scispace - formally typeset
F

Fuchun Guo

Researcher at Sichuan University

Publications -  31
Citations -  711

Fuchun Guo is an academic researcher from Sichuan University. The author has contributed to research in topics: Cancer & Tumor microenvironment. The author has an hindex of 14, co-authored 27 publications receiving 554 citations.

Papers
More filters
Journal ArticleDOI

Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice.

TL;DR: The effects of combining shRNA targeting PKM2 and docetaxel on human A549 lung carcinoma cells both in vivo and in vitro suggest that targeting tumor glycolysis can increase the efficacy of chemotherapy.
Journal ArticleDOI

Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency

TL;DR: This study provides the rationale for the clinical translation of CAR-modified T lymphocytes with VEGFR-1 specificity by electroporation and demonstrated the antitumor and anti-angiogenesis ability of V-1 CAR- modified T lymphocyte.
Journal ArticleDOI

Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation

TL;DR: Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resistance mutation and combination of EGFR tyrokinase inhibitors and NK cells adoptive immunotherapy may represent a potentially effective strategy for patients with non-small cell lung cancer.
Journal ArticleDOI

Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model

TL;DR: ThIORidazine was found to significantly inhibit breast tumor growth and the potential for thioridazine to be used in cancer therapy may be re-evaluated and investigated in clinical settings.
Journal ArticleDOI

Corrigendum: A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.

TL;DR: It is indicated that the FAP-modified whole-cell tumor vaccine induced strong antitumor immunity against both tumor cells and CAFs and reversed the immunosuppressive effects of tumors by decreasing the recruitment of immunOSuppressive cells and enhancing the recruitmentof effector T cells.